Biosimilars

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
My hospital recently evaluated remicade and inflectra. Guess what, bio-similar did not gain foot hold. Like the article said, price was not cheap enough like EU at 30 to 40% off. Plus, hospitals may have contracted discounts or rebate anyway with the brand name.

Why isn't bio-similar more aggressive? because of the reimbursement.
Remember that most biologics are with separately payable status. Thus, if you start cheap, your ASP, AWP will also lowered as result, and providers won't get paid as much.
Third party also play a HUGE role. our biggest payor in our state refused to pay for the bio-similar in the policy.
How about 340B pricing too? Pricing is not being very supported either.
Working six month behind brand, these bio-similar company needs to have better game plans.
As pharmacist, I am supportive of the efforts, but right now, my professional opinion sides with innovators for my organization.


Sent from my iPad using SDN mobile
 
Top